AKT1 and breast cancer: Further studies are needed in BC cell lines and animal models to verify the sensitizing activity of AKT inhibitors, and to assess the clinical efficacy of the AKT inhibitor and lapatinib combination using neratinib as a control (Ma et al., 2017).